Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial

Main Article Content

April W Armstrong
Sang Hee Park
Viktor Chirikov
Pierre Nicolas
Wei-Jhih Wang
Matthew J Colombo
Vardhaman Patel


psoriasis, moderate to severe, POETYK, deucravacitinib, TYK2 inhibitor




1. Armstrong AW, et al. J Am Acad Dermatol. 2022;S0190-9622 [online ahead of print].

2. Armstrong AW, et al. [poster] Presented at the American Academy of Dermatology Annual Meeting, March 25–29, 2022,
Boston, MA.

3. Armstrong AW, et al. J Dermatolog Treat. 2017;28:200-205.

4. Bushmakin AG, et al. Qual Life Res. 2011;20:491-498.

5. Warren RB, et al. J Eur Acad Dermatol Venereol. 2021;35:450-457.

6. Blauvelt A, et al. J Manag Care Spec Pharm. 2021;27:84-94.

Most read articles by the same author(s)

1 2 > >>